[Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrenergic receptors].
OBJECTIVE
To evaluate carvedilol effect on clinical state, norepinephrine (NE) and epinephrine (E) plasma concentration and lymphocyte beta 2-adrenoreceptor dependent cAMP synthesis in patients with primary pulmonary hypertension (PPH).


METHODS
14 patients with PPH were included in the study; 9 patients were treated by carvedilol; 5 patients were in the control group. The primary efficiency parameters were submaximal exercise measured by 60 min walk test, systolic pulmonary artery pressure (SPAP) measured by Doppler echocardiography, heart rate (HR) measured by 24-hour ECG-monitoring.


RESULTS
One month carvedilol treatment of PPH patients resulted in a significant HR reduction. There was a tendency to SPAP decrease, the 6-minute walk test results improved in IIINYHA patients.


CONCLUSIONS
Carvedilol therapy improves clinical state and evoked lymphocyte beta 2-adrenoceptor resensitization in PPH patients.
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002227:Carbazoles / Q000627:therapeutic use*; D002303:Cardiac Output, Low; D000077261:Carvedilol; D002395:Catecholamines / Q000097:blood*; D000242:Cyclic AMP / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D002395:Catecholamines; D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; D000077261:Carvedilol; D000242:Cyclic AMP
Karvedilol v lechenii bol'nykh pervichnoĭ legochnoĭ gipertonieĭ: vliianie na tiazhest' serdechnoĭ nedostatochnosti, stepen' legochnoĭ gipertonii, kontsentratsiiu katekholaminov v plazme krovi i zavisimyĭ ot beta-adrenoretseptorov sintez TsAMF v limfotsitakh.